Genmab A/S (GMAB)

Acerca de Genmab A/S

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Al 3 de noviembre de 2026, la acción de Genmab A/S (GMAB) subió a $55.38, un alza de 0.83% (+$0.46) frente al cierre anterior. En la sesión, las acciones han operado entre $55.10 y $56.50. Eso ubica a GMAB en el tercio superior de su rango de 52 semanas, de $23.62 a $59.97. Genmab A/S tiene una capitalización de mercado de aproximadamente $33.77 mil millones, con cerca de 2.44 millones de acciones negociadas.

Últimas noticias de GMAB

• Genmab Stock Price Shock Puts 3 Oncology Biotech Names In FocusYahoo Finance· 3 nov, 7:10 a.m. ET
• Can Genmab (CPSE:GMAB) Still Be Undervalued After Its Trial Wins?Yahoo Finance· 29 oct, 7:17 p.m. ET
• Genmab’s bispecific halves risk of death in first-line HNSCCclinicaltrialsarena.com· 29 oct, 12:24 p.m. ET
• Genmab soars to record highs after cancer drug succeeds in key trialbiopharmadive.com· 29 oct, 12:06 p.m. ET
• Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?stocktwits.com· 28 oct, 11:07 p.m. ET
• Genmab’s Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launchesmarketbeat.com· 28 oct, 5:04 p.m. ET
• Genmab Stock Surges to Record High After Stunning Cancer Drug ResultsYahoo Finance· 28 oct, 4:19 p.m. ET
• Genmab Stock Hits 52-Week High - Here's WhyYahoo Finance· 28 oct, 1:44 p.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de GMAB en un solo lugar? Crea una cuenta gratis →

• $GMAB $KOD $LZAGF What did I tell you? There’s always a reason behind my picks. 😉📈

  @Stekli27· 3 nov, 11:57 a.m. ET· Alcista

• $GMAB this will be back in the 40s

  @Itamar1234· 3 nov, 10:12 a.m. ET· Bajista

• $GMAB Bought 3000 shares of GMAB.

  @Orbit100· 2 nov, 11:19 a.m. ET· Alcista

• $LLY Added to the top 15 $GMAB Cruised 12 positions up to top 3 $CDNA moved 10 positions up to #1

  @satsandstocks· 1 nov, 11:13 a.m. ET· Alcista

• Highlights of the week. Some monsters in here, that AIOK div and the FDA approval on INO. Running out of room on this pic. $INO $AIOK $GMAB $GDYN $BOLT to name a few. Before the crowd! Link in bio for more. All trading and investing involves a risk of loss. Do your own due dil…

  @AlertsAndNews· 31 oct, 1:28 p.m. ET

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →